Merck Market Cap 2010-2022 | MRK

Merck market cap history and chart from 2010 to 2022. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Merck market cap as of March 23, 2023 is $265.03B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $265.029B $59.283B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $393.377B 14.87
Novo Nordisk (NVO) Denmark $331.955B 42.27
Eli Lilly (LLY) United States $314.520B 41.68
AbbVie (ABBV) United States $271.096B 11.03
Pfizer (PFE) United States $225.833B 6.08
Novartis AG (NVS) Switzerland $181.345B 13.41